Skip to main content
Premium Trial:

Request an Annual Quote

Meridian Inks Deal with Premier to Offer illumigene Molecular Tests

NEW YORK (GenomeWeb News) – Meridian Bioscience announced after the close of the market on Thursday that it has reached an agreement with Premier healthcare alliance to offer members of the alliance Meridian's illumigene C. difficile and illumigene Group B Streptococcus molecular tests.

Meridian will offer the two tests to the 2,500 US hospitals and more than 81,000 other healthcare sites that are part of Premier at specially negotiated prices.

The C. difficile test was cleared by the US Food and Drug Administration in July 2010 while the Group B Streptococcus test was cleared in December.

The illumigene tests are based on loop-mediated isothermal DNA amplification technology, which can yield results in less than one hour, Meridian said.

Premier is an alliance of hospitals and healthcare sites. It maintains the nation's most comprehensive repository of clinical, financial, and outcomes information, and operates a healthcare purchasing network.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.